In another move to generate income from out-licensing, AstraZeneca Plc has negotiated rights to two experimental dermatology drugs to LEO Pharma A/S of Denmark. The products are biologics and have not yet reached the market. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
